BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32572792)

  • 1. Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A.
    Fujitani K; Nakamura K; Mizusawa J; Kuwata T; Shimoda T; Katayama H; Kushima R; Taniguchi H; Yoshikawa T; Boku N; Terashima M; Fukuda H; Sano T; Sasako M;
    Gastric Cancer; 2021 Jan; 24(1):197-204. PubMed ID: 32572792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial.
    Iwasaki Y; Terashima M; Mizusawa J; Katayama H; Nakamura K; Katai H; Yoshikawa T; Ito S; Kaji M; Kimura Y; Hirao M; Yamada M; Kurita A; Takagi M; Lee SW; Takagane A; Yabusaki H; Hihara J; Boku N; Sano T; Sasako M
    Gastric Cancer; 2021 Mar; 24(2):492-502. PubMed ID: 33200303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer.
    Fujitani K; Mano M; Hirao M; Kodama Y; Tsujinaka T
    Ann Surg Oncol; 2012 Jun; 19(6):1936-43. PubMed ID: 22187120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery.
    Coimbra FJF; de Jesus VHF; Ribeiro HSC; Diniz AL; de Godoy AL; de Farias IC; Felismino T; Mello CAL; Almeida MF; Begnami MDFS; Dias-Neto E; Riechelmann RSP; da Costa WL
    Ann Surg Oncol; 2019 Oct; 26(11):3618-3626. PubMed ID: 31222685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.
    Ott K; Blank S; Becker K; Langer R; Weichert W; Roth W; Sisic L; Stange A; Jäger D; Büchler M; Siewert JR; Lordick F
    Langenbecks Arch Surg; 2013 Feb; 398(2):239-49. PubMed ID: 23269519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
    Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
    Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of anaemia in oesophago-gastric cancer patients undergoing curative treatment by means of neoadjuvant chemotherapy and surgery.
    Chan BY; McKinlay S; Forshaw M; MacDonald A; Maitra R; Orizu M; McSorley ST
    Surg Oncol; 2021 Sep; 38():101585. PubMed ID: 33930843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological response measured using virtual microscopic slides for gastric cancer patients who underwent neoadjuvant chemotherapy.
    Kawai S; Shimoda T; Nakajima T; Terashima M; Omae K; Machida N; Yasui H
    World J Gastroenterol; 2019 Sep; 25(35):5334-5343. PubMed ID: 31558877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic significance of textbook outcome in advanced gastric patients who underwent neoadjuvant chemotherapy followed by surgical resection].
    Tang YH; Huang ZN; Chen QY; Li P; Xie JW; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Zheng CH; Huang CM
    Zhonghua Wai Ke Za Zhi; 2024 May; 62(5):379-386. PubMed ID: 38548605
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma.
    Sada YH; Smaglo BG; Tan JC; Tran Cao HS; Musher BL; Massarweh NN
    J Natl Compr Canc Netw; 2019 Feb; 17(2):161-168. PubMed ID: 30787129
    [No Abstract]   [Full Text] [Related]  

  • 11. Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy.
    Koh YW; Park YS; Ryu MH; Ryoo BY; Park HJ; Yook JH; Kim BS; Kang YK
    Am J Surg Pathol; 2013 Jul; 37(7):1022-9. PubMed ID: 23715160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.
    Liu Y; Zhang KC; Huang XH; Xi HQ; Gao YH; Liang WQ; Wang XX; Chen L
    World J Gastroenterol; 2018 Jan; 24(2):257-265. PubMed ID: 29375211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
    Persiani R; D'Ugo D; Rausei S; Sermoneta D; Barone C; Pozzo C; Ricci R; La Torre G; Picciocchi A
    J Surg Oncol; 2005 Mar; 89(4):227-36; discussion 237-8. PubMed ID: 15726615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy.
    Tong Y; Zhao Y; Shan Z; Zhang J
    BMC Cancer; 2021 Jan; 21(1):4. PubMed ID: 33402124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response.
    Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy
    Li Y; Ma FH; Xue LY; Tian YT
    World J Gastroenterol; 2020 Feb; 26(8):818-827. PubMed ID: 32148379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
    Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
    Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.